Cleve Clin J Med. 2020 Dec 31;88(1):47-58. doi: 10.3949/ccjm.88a.20088.
ABSTRACT
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are an exceptionally versatile class of medication, and their glycemic and nonglycemic benefits could help millions of patients with type 2 diabetes. Of note, they have been shown to improve cardiac and renal outcomes, much-needed benefits in patients with type 2 diabetes, who are at a higher risk for developing cardiac and renal dysfunction than those who do not have diabetes. The indications for SGLT-2 inhibitors may continue to expand as ongoing clinical trials provide more insight into these drugs.
PMID:33384315 | DOI:10.3949/ccjm.88a.20088